Financial Performance - The company achieved operating revenue of CNY 2,554,609,066.22 in 2022, representing a year-on-year growth of 19.45%[20] - Net profit attributable to shareholders reached CNY 369,808,047.91, an increase of 76.99% compared to the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 369,204,785.35, reflecting a significant increase of 453.58% year-on-year[20] - The company's revenue increased by CNY 416.02 million, a growth of 19.45%, primarily due to higher sales of new active ingredients[40] - The company's main business revenue for 2022 reached RMB 2,544.92 million, representing a year-on-year growth of 19.67%[66] - The company reported a basic earnings per share of ¥1.49, a significant increase of 77.38% from ¥0.84 in the previous year[138] - The weighted average return on equity rose to 13.18%, an increase of 5.09 percentage points compared to the previous year[138] - The company reported a significant increase in net cash flow from operating activities, amounting to CNY 837,377.04 million, a year-on-year increase of 128.46%[72] Production and Capacity Expansion - The sales of the main product, New Active Substance, reached 6.16 million units, with sales revenue increasing by 33.71% year-on-year[26] - The company is expanding its production capacity for New Active Substance, with a planned annual capacity of 15 million units[33] - A new production base in Lhasa received its drug production license on February 15, 2022, enhancing the company's production capabilities[33] - The company has established a high-altitude medicinal herb cultivation base in Tibet, successfully reducing the incidence of root rot in Rhodiola rosea and improving survival rates[61] - The company has implemented a production transfer for Yimuduo in the Chinese market, completing the necessary method validation and quality management system setup[61] Research and Development - Research and development expenses rose by CNY 27.27 million, an increase of 44.81%, mainly due to the capitalization of expenses related to a vaccine project[42] - The company’s R&D expenses increased by 44.81% to CNY 88,130.46 million, indicating a strong commitment to innovation[72] - The number of R&D personnel is 37, accounting for 6% of the total workforce[80] - Research and development expenses for vaccine technology transfer amounted to 2,524.33 million RMB, with a decrease of 42.09% compared to the previous period[170] Market and Sales Strategy - The company is actively expanding its online sales channels and optimizing hospital market product offerings[66] - The company plans to expand its market presence and enhance its product offerings in response to favorable industry policies and growing healthcare needs[34] - The company has exclusive marketing rights for four in-development products in China, including biodegradable drug-eluting stents, which are expected to contribute to future revenue growth[111] - The company is focusing on the main business and exploring new sales models in response to national medical reform policies[180] Financial Management - The company received government subsidies amounting to CNY 6.39 million, up from CNY 2.46 million in the previous year[53] - Financial expenses decreased by CNY 2.46 million, influenced by increased interest income and reduced foreign exchange losses[42] - The company reported a significant decrease in accounts payable by 58.26%, totaling ¥42,210,412.37 compared to ¥101,136,917.95 last year, indicating improved cash flow management[104] - The company is actively managing liquidity risk by maintaining sufficient cash and cash equivalents to meet operational needs[152] Product Performance - Sales revenue from the main product, Xinhua Su, accounted for 88.44% of total annual sales, with a year-on-year increase of 33.71%[66] - During the reporting period, Xinhua Su sold 6.16 million units, generating sales revenue of RMB 2,250.85 million, while sales revenue from Yimuduo decreased by 45.20% to RMB 165.32 million[60] - Revenue from cardiovascular treatments reached ¥245,924.75 million, representing a year-over-year increase of 20.65%[117] - Revenue from cold medications surged by 142.58% year-over-year, totaling ¥1,472.37 million, with a gross margin of 88.24%[117] Corporate Recognition and Compliance - The company is recognized as the first high-tech pharmaceutical listed enterprise in Tibet and has established multiple production bases compliant with GMP standards[34] - The company has been awarded "Excellent Unit for National Drug Adverse Reaction Monitoring" for two consecutive years, highlighting its commitment to drug safety[34] - The company has been recognized as the first "Pharmaceutical Standard Research Base" in Tibet by the local drug supervision authority[61] Future Plans - The company plans to continue leveraging its unique ecological resources for the development of traditional Tibetan medicine, ensuring long-term growth[70] - The company plans to enhance its product portfolio through acquisitions of mature drugs and increase R&D efforts for new products[180] - The company plans to distribute cash dividends of 7.46 RMB per 10 shares to all shareholders, based on the total share capital as of the dividend registration date[143]

证券代码：600211 证券简称：西藏药业 公告编号：2023-006 西藏诺迪康药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2023 年 3 月 16 日 15:00-16:00。 ●会议召开方式：本次业绩说明会将采用网络方式举行。 ●投资者可于 2023 年 3 月 15 日（星期三）前将相关问题通过电子邮件的形式发送至邮 箱：chenxu@xzyy.cn，本公司将在 2022 年度业绩说明会上对投资者普遍关注的问题进行回答。 本公司将于 2023 年 3 月 11 日在《中国证券报》《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）披露公司 2022 年年度报告，并将于 2023 年 3 月 16 日 15:00-16:00 召开 2022 年度业绩说明会。 说明会；同时公司将通过该平台及时回答投资者的提问。 一、说明会类型 本次业绩说明会以网络方式召开，公司将针对 2022 年度的经营成果 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥614,958,157.89, representing a year-on-year increase of 17.36%[4] - The net profit attributable to shareholders for Q3 2022 was ¥180,535,996.25, reflecting a significant increase of 50.14% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥178,204,991.39, up by 43.86% year-on-year[4] - Total revenue for the first three quarters of 2022 reached ¥1,958,146,141.99, an increase of 25.3% compared to ¥1,561,918,321.68 in the same period of 2021[29] - The company's net profit for the first three quarters of 2022 reached CNY 446,968,616.30, an increase from CNY 421,642,073.47 in the same period of 2021, representing a growth of approximately 6.5%[32] - The total profit for the period was CNY 512,635,895.59, up from CNY 471,085,009.80 in the previous year, marking an increase of around 8.8%[32] - The company recorded a total profit of ¥521.63 million for the first three quarters of 2022, up 36.5% from ¥382.18 million in 2021[43] Cash Flow - The net cash flow from operating activities for the period was ¥125,909,545.11, marking a substantial increase of 38.74% compared to the previous year[4] - The net cash flow from operating activities for Q3 2022 was $601.1 million, an increase of 38.8% compared to $433.3 million in Q3 2021[35] - The net cash flow from investment activities increased by ¥579 million compared to the previous year, mainly due to the maturity of structured bank deposits[10] - The net cash flow from financing activities decreased by RMB 231 million compared to the same period last year, primarily due to an increase in bank loan repayments by RMB 282 million and a decrease in dividends paid by RMB 43 million[14] - The net cash flow from operating activities decreased to ¥178.01 million in 2022 from ¥347.66 million in 2021, reflecting a decline of 48.9%[45] - The company reported a net cash outflow from investing activities of ¥76.43 million in 2022, a significant improvement from a net outflow of ¥354.30 million in 2021[45] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥4,328,100,029.27, an increase of 13.82% from the end of the previous year[6] - Current assets as of September 30, 2022, totaled ¥2,710,344,422.08, compared to ¥2,181,906,816.29 at the end of 2021, marking a growth of 24.2%[25] - Total liabilities amounted to ¥1,203,281,204.56, compared to ¥1,157,635,453.49 in the previous year, indicating an increase of 3.9%[27] - The total assets reached $3.75 billion as of September 30, 2022, compared to $3.39 billion at the end of 2021, indicating an increase of 10.8%[41] - The company reported a total liability of $560.0 million as of September 30, 2022, down from $594.7 million at the end of 2021, a decrease of 5.8%[41] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,413, with the top ten shareholders holding significant stakes, including Tibet Kangzhe Enterprise Management Co., Ltd. with 32.28%[16] - Tibet Kangzhe Enterprise Management Co., Ltd. holds 80,033,379 shares, while Tibet Huaxi Pharmaceutical Group Co., Ltd. holds 44,072,000 shares, representing 17.78%[16] - The top ten shareholders include both domestic and foreign entities, with significant holdings by domestic non-state-owned legal persons[16] - The company has not disclosed any related party transactions among the top shareholders, except for known agreements among certain entities[17] Research and Development - Research and development expenses increased by 318.18% to ¥6,080.03 million, primarily due to the capitalization of expenses related to the new COVID-19 vaccine project[10] - Research and development expenses increased significantly to CNY 79,908,994.62 from CNY 19,108,743.69, reflecting a growth of approximately 317.5%[32] - Research and development expenses surged to ¥64.14 million in the first three quarters of 2022, compared to only ¥4.98 million in the same period of 2021, indicating a substantial focus on innovation[43] Financial Expenses - The company reported a 32.81% increase in income tax expenses, amounting to an increase of ¥1,622.43 million, driven by higher sales revenue[10] - The company experienced a 348.12% increase in financial expenses, totaling an increase of ¥825.45 million, attributed to new bank loans and foreign exchange losses[10] - The financial expenses, including interest expenses, increased to CNY 10,625,628.75 from CNY 2,371,166.48, reflecting a rise of approximately 348.5%[32] - The financial expenses for the first three quarters of 2022 were ¥857.72 thousand, compared to a financial income of ¥748.38 thousand in the same period of 2021[43] Cash Management and Investments - The company has a total of RMB 39 million in unexpired structured deposits, with no overdue amounts reported[18] - The company has engaged in various structured deposits with multiple banks, with amounts ranging from RMB 1,000 million to RMB 8,000 million and annualized returns between 1.3% and 3.4%[20] - The company’s investment activities generated cash inflows of ¥959.09 million in 2022, a substantial increase from ¥151.52 million in 2021[45] - The company plans to continue its investment strategies and cash management practices to optimize financial performance in the future[18]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,343,187,984.10, representing a 29.41% increase compared to ¥1,037,935,554.97 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 12.07% to ¥262,250,027.50 from ¥298,236,915.19 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥273,073,032.70, down 6.70% from ¥292,681,395.73 in the previous year[19]. - The net cash flow from operating activities increased by 29.79% to ¥475,187,904.79 compared to ¥366,118,744.91 in the same period last year[19]. - Basic earnings per share for the first half of 2022 were ¥1.06, down 11.67% from ¥1.20 in the same period last year[19]. - The weighted average return on net assets decreased by 1.64 percentage points to 9.50% from 11.14% in the previous year[19]. - The company achieved operating revenue of 1,343.19 million yuan, a year-on-year increase of 29.41%[33]. - Net profit attributable to shareholders decreased by 12.07% to 262.25 million yuan, while the net profit excluding non-recurring gains and losses was 273.07 million yuan, reflecting a growth of 17.83% year-on-year[35]. - The company reported a total profit of CNY 310,320,683.72 for the first half of 2022, down from CNY 334,100,231.00 in the same period of 2021[133]. - The company reported a significant increase in cash received from investment recoveries, totaling CNY 550,000,000.00, compared to CNY 150,000,000.00 in the previous year[145]. Business Operations - The company's main business is in the pharmaceutical manufacturing industry, producing and selling capsule agents, biological agents, granules, and film agents, with key products in cardiovascular, liver and gallbladder, and pain relief areas[25]. - In the first half of 2022, the company's main business revenue reached RMB 1.34 billion, a year-on-year increase of 29.34%[25]. - Sales of the cardiovascular products, including Xinhuisu and Yimuduo, accounted for 97.47% of total sales, with Xinhuisu alone contributing 88.95% of the half-year sales revenue, growing by 45.36% compared to the same period last year[25]. - The company has established three GMP-compliant production bases for biological, Tibetan, and traditional Chinese medicine products, and one GAP-compliant Tibetan medicinal material planting base[25]. - The company is undergoing the conversion of the marketing authorization holder for Yimuduo, ensuring compliance with regulatory requirements and maintaining product quality management systems[25]. - The company has invested significantly in high-tech biopharmaceutical products to expand its product pipeline and address the shortage of research and development reserves[35]. - The company has established a comprehensive marketing system across the country, leveraging resources from its major shareholder to enhance market competitiveness[32]. - The company is actively pursuing external investments and collaborations to increase product reserves and expand its business lines[35]. Research and Development - The company incurred development expenses of ¥54,023,300 related to the COVID-19 vaccine project during the reporting period[19]. - R&D expenses surged by 1,384.53% to approximately CNY 77.14 million, largely due to the capitalization of development costs related to the Russian COVID-19 vaccine project[45]. - Research and development expenses rose significantly to CNY 77,139,512.22, compared to CNY 5,196,240.98 in the previous year, indicating a focus on innovation[130]. - The company plans to incorporate post-marketing research for some traditional Chinese medicine products into its development strategy to ensure market supply and demand[29]. Financial Position - The total assets at the end of the reporting period were ¥4,046,895,053.31, a 6.42% increase from ¥3,802,655,776.83 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 8.89% to ¥2,864,301,772.72 from ¥2,630,358,934.53 at the end of the previous year[19]. - Trading financial assets increased by 35.95% to ¥731,218,306.74, primarily due to an increase in bank structured deposits[48]. - Other current assets decreased by 80.81% to ¥16,170,269.87, mainly due to VAT refund impacts from subsidiaries[48]. - The total current assets increased to ¥2,453,960,478.61 from ¥2,181,906,816.29, reflecting a growth of approximately 12.4%[121]. - The company reported a decrease in cash and cash equivalents to ¥13,369,952.96 from ¥84,077,331.47, a decline of about 84.06%[125]. - The total liabilities amounted to ¥1,164,989,747.61, compared to ¥1,157,635,453.49, showing a growth of around 0.28%[123]. - The total equity attributable to the parent company at the end of the reporting period is approximately 2.88 billion, a decrease of 161.59 million compared to the previous period[152]. Environmental and Social Responsibility - The company has invested over 3.1 million yuan in poverty alleviation and rural revitalization efforts, including direct financial support and donations of pharmaceuticals[84]. - The company has signed a four-year assistance agreement to donate pharmaceuticals worth 446,000 yuan and cash donations of 566,000 yuan to support local health initiatives[87]. - Chengdu Nodi Kang Bio-Pharmaceutical Co., Ltd. reported no exceedance of pollutant discharge limits and no environmental accidents in the first half of 2022[67]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental protection department[72]. - The wastewater treatment facility has a design capacity of 240 m³/d and has been operating stably since its establishment in 2002[70]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 57,038[112]. - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 80,033,379 shares, accounting for 32.28% of total shares[112]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[63]. - The company has 11 subsidiaries included in the consolidated financial statements for this period[2]. Regulatory Compliance - The company operates under the continuous operation basis, with no significant doubts about its ability to continue operations for the next 12 months[3]. - The company adheres to the enterprise accounting standards, ensuring that its financial statements accurately reflect its financial position and operating results[4]. - The company follows a control-based principle for determining the scope of consolidated financial statements, including all subsidiaries under its control[178].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 656,135,778.33, representing a year-on-year increase of 32.74%[5] - The net profit attributable to shareholders for Q1 2022 was RMB 174,668,206.63, reflecting an increase of 11.13% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 182,566,204.88, up by 27.68% year-on-year[5] - The basic earnings per share for Q1 2022 was RMB 0.70, marking an increase of 11.11% year-on-year[5] - The diluted earnings per share for Q1 2022 was also RMB 0.70, reflecting an increase of 11.11% compared to the same period last year[5] - The total operating revenue for Q1 2022 was CNY 656,135,778.33, an increase of 32.8% compared to CNY 494,293,289.21 in Q1 2021[28] - The net profit for Q1 2022 was CNY 176,249,968.12, compared to CNY 158,563,524.68 in Q1 2021, representing an increase of 11.0%[30] - Total comprehensive income amounted to CNY 171,724,467.56, an increase from CNY 169,334,500.48 year-over-year[32] - Basic and diluted earnings per share increased to CNY 0.70 from CNY 0.63 in the previous year[32] Cash Flow - The net cash flow from operating activities for Q1 2022 was RMB 242,413,333.94, which is an increase of 10.03% compared to the previous year[5] - Cash inflow from operating activities reached CNY 727,580,990.05, compared to CNY 540,272,824.77 in the first quarter of 2021, reflecting a significant growth[34] - Net cash flow from operating activities was CNY 242,413,333.94, up from CNY 220,317,632.56 year-over-year[34] - Cash inflow from investment activities totaled CNY 302,746,133.10, a substantial increase compared to CNY 707.96 in the previous year[34] - Net cash flow from investment activities was negative at CNY -98,061,380.28, improving from CNY -324,030,839.64 year-over-year[34] - Cash inflow from financing activities was CNY 35,999,521.37, down from CNY 40,079,075.99 in the previous year[34] - The net increase in cash and cash equivalents was CNY 172,226,199.18, contrasting with a decrease of CNY -63,355,434.79 in the previous year[34] - The ending balance of cash and cash equivalents was CNY 928,640,467.56, up from CNY 705,076,989.66 year-over-year[34] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to RMB 4,036,144,500.18, which is a 6.14% increase from the end of the previous year[5] - The total assets as of Q1 2022 were CNY 4,036,144,500.18, compared to CNY 3,802,655,776.83 at the end of the previous year, showing a growth of 6.1%[28] - The company reported an increase in accounts receivable to RMB 459,919,020.96 from RMB 471,373,735.72, indicating a decrease of approximately 2.43%[25] - The company’s total liabilities decreased from RMB 1,200,000,000 to RMB 1,150,000,000, showing a reduction of about 4.17%[25] - The total liabilities for Q1 2022 were CNY 1,219,399,709.29, an increase from CNY 1,157,635,453.49 in the previous year, reflecting a rise of 5.3%[28] - The company reported a decrease in accounts payable to CNY 82,490,089.62 from CNY 101,136,917.95, a decline of 18.5%[28] - The total equity attributable to shareholders increased to CNY 2,800,501,640.60 from CNY 2,630,358,934.53, reflecting a growth of 6.5%[28] Investments and R&D - The significant increase in operating revenue was primarily driven by a substantial rise in the sales of new products[10] - Research and development expenses in Q1 2022 were CNY 9,926,809.57, significantly higher than CNY 1,418,199.60 in Q1 2021, indicating a focus on innovation[30] - The company has secured exclusive sales rights for four in-development products in the Chinese market, including a fully biodegradable drug-eluting stent system and a high-pressure balloon dilation catheter[16] - The company has obtained a pharmaceutical production license for its new production base in Lhasa Economic and Technological Development Zone[16] Dividends - The company’s annual dividend plan was approved, distributing RMB 0.338 per share to all shareholders, based on a total share capital of 247,937,843 shares[16] Taxation - The company reported a tax expense of CNY 87,355,407.49, compared to CNY 53,035,392.45 in the previous year, indicating increased tax obligations[34]

Financial Performance - The company's operating revenue for 2021 was approximately ¥2.14 billion, representing a 55.75% increase compared to ¥1.37 billion in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥208.94 million, a decrease of 50.03% from ¥418.10 million in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥66.69 million, down 81.74% from ¥365.33 million in 2020[21]. - The basic earnings per share for 2021 was ¥0.84, a decline of 50.30% compared to ¥1.69 in 2020[22]. - The total assets of the company at the end of 2021 were approximately ¥3.80 billion, an increase of 29.15% from ¥2.94 billion at the end of 2020[21]. - The net cash flow from operating activities for 2021 was approximately ¥366.53 million, a decrease of 14.39% from ¥428.17 million in 2020[21]. - The company's net assets attributable to shareholders at the end of 2021 were approximately ¥2.63 billion, a slight increase of 2.11% from ¥2.58 billion at the end of 2020[21]. - The company reported a weighted average return on equity of 8.09%, a decrease of 7 percentage points[25]. - The weighted average return on equity after deducting non-recurring gains and losses was 2.58%, down 10.60 percentage points[25]. Product Sales and Market Performance - Sales of the new product "New Vitality" reached 4.59 million units, with sales revenue increasing by 75.57% compared to the previous year[33]. - Sales of the main product, Xinhuisu, reached 4.59 million units with revenue of 1.68 billion yuan, a year-on-year increase of 75.57%; IMDUR sales revenue was 301.65 million yuan, up 8.31%[37]. - The main business income from cardiovascular products, including Xinhuisu, Yimuduo, and Nuodikan, accounted for 95.85% of total revenue, with Xinhuisu alone contributing 79.16% and growing by 75.57% compared to the previous year[50]. - The company launched a new product, Nuodikan granules, in 2021, which offers higher absorption and bioavailability compared to the capsule form[49]. - The company’s domestic revenue was 1,928.56 million RMB, with a year-on-year growth of 64.54%[60]. - The company’s revenue from external use products was CNY 5,051.21 million, with a gross margin of 72.16%, and a year-on-year revenue increase of 2.06%[90]. Research and Development - The company has invested significantly in high-tech biopharmaceutical products and formed strategic partnerships to expand its product portfolio, including in the medical device and COVID-19 vaccine sectors[49]. - The company is conducting research on artificial cultivation of Rhodiola rosea, achieving a significant increase in seedling survival rates and meeting pharmacopoeia requirements for active ingredient content[40]. - The company has initiated a clinical trial for the recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) eye drops, which showed good safety but requires further exploration of efficacy, leading to a temporary halt in development[91]. - The company’s R&D investment amounted to 6,011.07 million RMB, representing 4.93% of operating revenue and 3.28% of net assets, with a capitalization ratio of 0%[99]. - The R&D investment for the rhIL-1Ra eye drops project was 74.65 million RMB, which is a 64.48% decrease compared to the same period last year[101]. Operational and Strategic Initiatives - The company is preparing for the market launch of the high-pressure balloon dilation catheter, which has obtained the necessary medical device registration certificates[36]. - The company has established a new production base in Lhasa, which received its drug production license on February 15, 2022, enhancing production capacity to meet market demand[41]. - The company has paused further development of the rhIL-1Ra eye drop project after initial clinical trials showed good safety but uncertain efficacy[40]. - The company has implemented electronic management of marketing channels for real-time data control and has established an expert system for academic promotion to enhance product marketing[37]. - The company is focusing on digital transformation and plans to establish a data center for business data visualization[118]. Financial Management and Governance - The company emphasizes the importance of maintaining independent operations from its controlling shareholder, ensuring compliance with legal and regulatory requirements[125]. - The company conducted four shareholder meetings during the reporting period, ensuring compliance with legal procedures and protecting the rights of all shareholders, particularly minority shareholders[125]. - The company has not experienced any new instances of fund occupation by major shareholders or related parties during the reporting period, maintaining financial integrity[125]. - The company has a structured process for determining the remuneration of its directors and senior management[139]. - The company has maintained a focus on compliance and governance with the appointment of new independent directors[136]. Environmental and Social Responsibility - The company has maintained compliance with national environmental standards, with no pollution incidents or penalties reported for several years[187]. - The company has established an emergency response plan for environmental incidents, which has been filed with the ecological environment department, with filing number 510104-2021-L-1[172]. - The company has participated in the "Ten Thousand Enterprises Helping Ten Thousand Villages" initiative for the third time, donating funds and medicines[188]. - The "Tibetan Medicine Modernization Comprehensive Technology Industrial Park" project has provided nearly 100 job opportunities for local farmers[188]. - The company has integrated social responsibility into its development strategy, focusing on sustainable growth and community support[4].

Financial Performance - The company's revenue for Q3 2021 reached ¥523,982,766.71, representing a 45.13% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥120,247,586.03, reflecting a 15.02% year-over-year growth[5] - The net profit excluding non-recurring gains and losses was ¥123,869,652.33, up 17.30% from the previous year[5] - The basic earnings per share for the quarter was ¥0.49, an increase of 22.50% year-over-year[7] - The company reported a 57.83% increase in revenue year-to-date, totaling ¥1,561,918,321.68[5] - Net profit for the third quarter reached ¥421,642,073.47, compared to ¥326,895,974.92 in the same period last year, reflecting a year-over-year increase of about 29%[36] - Revenue for the first three quarters of 2021 was ¥1,561,918,321.68, significantly higher than ¥989,591,676.46 in the first three quarters of 2020, marking a growth of approximately 58%[34] - Operating profit for the third quarter was ¥471,678,971.57, compared to ¥366,734,833.20 in the previous year, indicating an increase of around 28.6%[36] - Total comprehensive income for the third quarter of 2021 reached CNY 414,507,247.14, an increase from CNY 368,002,583.40 in the same period of 2020, representing a growth of approximately 12.6%[37] - Basic and diluted earnings per share for the third quarter of 2021 were both CNY 1.69, compared to CNY 1.50 in the same period of 2020, reflecting an increase of 12.7%[37] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,753,629,033.27, a 27.49% increase from the end of the previous year[7] - Total assets increased to ¥3,753,629,033.27, up from ¥2,944,288,278.85, representing a growth of approximately 27.3% year-over-year[34] - Total liabilities increased to ¥890,558,968.59, up from ¥333,076,838.24, representing a growth of about 167%[34] - The company's equity attributable to shareholders reached ¥2,860,986,375.54, compared to ¥2,576,085,000.59, reflecting an increase of approximately 11%[34] - The company's total current assets increased to ¥1.70 billion as of September 30, 2021, compared to ¥1.35 billion at the end of 2020, reflecting a growth of approximately 25.7%[31] - The company's total assets as of the end of the reporting period were CNY 1,351,114,990.65, showing stability in asset management[41] - Total assets amounted to approximately $2.94 billion, a slight decrease from $2.95 billion in the previous period[46] - Non-current assets totaled approximately $1.59 billion, with a minor decrease from $1.60 billion[46] - Current liabilities were approximately $333.08 million, down from $334.29 million[46] - Total liabilities reached approximately $355.91 million, compared to $359.09 million previously[46] Cash Flow - The company's cash flow from operating activities showed a net decrease of 45.64%, totaling ¥67,133,392.80[5] - Net cash flow from operating activities increased by 123 million CNY year-on-year, mainly due to a 532 million CNY increase in cash received from product sales and services[14] - Cash inflow from operating activities totaled CNY 1,700,929,375.39, up from CNY 1,226,507,780.95 in the previous year, indicating a growth of approximately 38.6%[39] - Net cash flow from operating activities was CNY 433,252,137.71, compared to CNY 310,450,570.04 in the same period of 2020, marking an increase of about 39.5%[39] - Cash outflow from investing activities amounted to CNY 882,114,344.97, a decrease from CNY 1,125,306,576.46 in the previous year, showing a reduction of approximately 21.6%[39] - Net cash flow from investing activities was negative CNY 730,362,982.04, compared to negative CNY 93,355,104.33 in the same period of 2020, indicating a significant increase in cash outflow[39] - The company reported a total cash inflow from financing activities of CNY 425,468,116.74, compared to CNY 50,000,000.00 in the same period of 2020, reflecting a substantial increase[39] Expenses - Research and development expenses increased by 407.26% year-over-year, amounting to ¥1,534.17 million, indicating a significant investment in product development[12] - Sales expenses for the third quarter were ¥829,022,210.31, compared to ¥480,236,526.82 in the previous year, indicating an increase of about 72.6%[36] - The company has seen an increase in donations, leading to an increase in other expenses by 36.06 million CNY compared to the same period last year[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,064[15] - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 80,033,379 shares, accounting for 32.28% of total shares[15] - The second-largest shareholder, Tibet Huaxi Pharmaceutical Group Co., Ltd., holds 44,072,000 shares, accounting for 17.78% of total shares[15] Investments and Acquisitions - The company completed the acquisition of IMDUR® assets from AstraZeneca for $190 million, with the transfer of sales rights effective from May 1, 2016, covering approximately 40 countries and regions[22] - The company holds a 3.35% equity stake in Simi Biological after converting a previous payment of ¥70 million into an investment[22] - The company has committed to supplying a minimum of 40 million doses of the Sputnik-V vaccine in 2021, contingent upon successful technology transfer and production[22] - The company has invested ¥20 million in structured deposits as part of its wealth management strategy, with expected annualized returns ranging from 1.3% to 3.40%[27] - The company has received ¥3 million in compensation from Simi Biological, related to the equity investment[22] Other Income and Expenses - Interest income from financial products decreased, while short-term loan interest expenses increased, leading to a reduction in other income by 49.09 million CNY compared to the same period last year[14] - Other income increased by 23.64 million CNY, primarily due to compensation received from a microbial company[14] - The company did not receive government subsidies in the current period, impacting other income negatively[14] Tax and Regulatory Matters - Deferred tax assets increased to ¥27,688,605.61 from ¥23,436,990.63, showing a growth of approximately 18.5%[34] - The company is awaiting verification from Russian authorities for the technology transfer related to the COVID-19 adenovirus vaccine project, which is currently in progress[22] Foreign Exchange and Goodwill - The company incurred a foreign exchange loss of CNY 7,134,826.33 during the quarter, compared to a loss of CNY 21,740,289.93 in the same period of the previous year[39] - The company holds goodwill valued at approximately $8.88 million[46]

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥1,037,935,554.97, representing a 65.13% increase compared to ¥628,551,332.41 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥298,236,915.19, up 35.62% from ¥219,907,115.95 in the previous year[23]. - The net cash flow from operating activities was ¥366,118,744.91, showing a significant increase of 95.83% compared to ¥186,958,325.57 in the same period last year[25]. - The total assets at the end of the reporting period were ¥3,455,838,590.41, a 17.37% increase from ¥2,944,288,278.85 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company increased by 6.19% to ¥2,735,515,757.90 from ¥2,576,085,000.59 at the end of the previous year[25]. - Basic earnings per share for the first half of 2021 were ¥1.20, a 9.09% increase from ¥1.10 in the same period last year[26]. - The weighted average return on net assets increased by 2.29 percentage points to 11.14% from 8.85% in the previous year[26]. - The company reported a net profit after deducting non-recurring gains and losses of ¥292,681,395.73, which is a 64.81% increase from ¥177,587,807.95 in the same period last year[25]. - The diluted earnings per share also stood at ¥1.20, reflecting a 9.09% increase compared to the previous year[26]. Revenue Sources - The company's main business revenue for the first half of 2021 reached 1.036 billion RMB, with cardiovascular products accounting for 96.17% of total sales[32]. - Sales of the product Xinhuxin increased by 99.95% year-on-year, contributing 79.15% to the total revenue for the period[32]. - The product Yimuduo's sales accounted for 14.68% of total revenue, showing a decline of 2.95% compared to the previous year[32]. Investment and Growth Strategies - The company is actively pursuing new investment projects to create additional profit growth points amid increasing demand in the pharmaceutical market due to aging population[32]. - The company employs a "sales-driven production" model, adjusting production plans based on annual sales forecasts from distributors[32]. - The company has implemented a procurement strategy that includes public bidding for raw materials to optimize costs amid fluctuating market prices[32]. - The company anticipates growth in the pharmaceutical industry as hospitals and clinics recover from the pandemic, supported by ongoing policy reforms[32]. Research and Development - The company has invested significantly in high-tech biopharmaceutical products through strategic partnerships, expanding its product reserves in the medical device and COVID-19 vaccine sectors[35][39]. - The company’s new product development includes a recombinant human interleukin-1 receptor antagonist eye drop project, which has completed Phase IIa clinical trials[39]. - The company’s production lines have passed GMP compliance checks, ensuring robust sales growth and product safety[35]. Financial Position and Assets - The company reported a total comprehensive income of ¥288,042,296.47 for the first half of 2021, compared to ¥244,555,766.60 in the same period of 2020, indicating an increase of about 17.7%[123]. - The total assets and shareholders' equity amounted to ¥2,809,803,448.96 and ¥2,305,185,887.92 respectively, indicating a solid financial position[120]. - The company reported a long-term equity investment of RMB 118,136,863.58, slightly down from RMB 119,229,304.09[108]. Environmental and Social Responsibility - The company invested over 2.7 million yuan in poverty alleviation and rural revitalization efforts in the first half of 2021[78]. - The company has been conducting artificial cultivation research of plateau medicinal plants in Linzhi City and building a modern comprehensive Tibetan medicine industrial park in Lhasa[78]. - The company has established an emergency response plan for environmental incidents, covering all potential environmental impact accidents[72]. Shareholder Information - A cash dividend of RMB 0.51 per share (including tax) was distributed to shareholders based on a total share capital of 247,937,843 shares[87]. - The company has a total of 68,215 common shareholders as of the end of the reporting period[96]. - The top shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 80,033,379 shares, accounting for 32.28% of the total shares[97]. Risks and Challenges - The company faces risks in new drug development, particularly with the rhIL-1Ra eye drop project, which may encounter clinical efficacy and safety issues[58]. - Rising costs of raw materials, labor, and compliance with new environmental regulations have put substantial pressure on the production costs of traditional Chinese medicine products[58]. - The company reported a significant impact on sales revenue due to the recurring COVID-19 pandemic, which may lead to fluctuations in performance for the fiscal year 2021[56]. Corporate Governance - There were changes in the board of directors, with the election of a new independent director, Huang Wei, following the resignation of Liu Chuncheng[63]. - The company has not reported any non-compliance issues related to its major shareholders or related parties during the reporting period[82].

Financial Performance - Operating revenue for the period was ¥494,293,289.21, representing a significant increase of 66.55% year-on-year[11]. - Net profit attributable to shareholders was ¥157,178,601.77, up 22.29% from the same period last year[11]. - The company reported a net profit excluding non-recurring gains and losses of ¥142,985,548.63, a year-on-year increase of 66.26%[11]. - Operating revenue for the first quarter was CNY 494.29 million, an increase of CNY 197.51 million or 66.55% compared to the same period last year, driven by significant sales growth of the biological product[24]. - The company reported a significant increase in sales revenue from CNY 391,731,090.91 in Q1 2020 to CNY 539,039,417.33 in Q1 2021, marking a growth of 37.7%[46]. - The company’s earnings per share (EPS) for Q1 2021 was ¥0.63, down from ¥0.73 in Q1 2020[43]. - The total comprehensive income for Q1 2021 was ¥169,334,500.48, an increase from ¥153,131,762.47 in Q1 2020[43]. Cash Flow - Net cash flow from operating activities amounted to ¥220,317,632.56, reflecting a 59.23% increase compared to the previous year[11]. - The net cash flow from investing activities decreased by CNY 3,525.20 million, primarily due to payments for project construction and milestone payments to partners[25]. - Cash flow from operating activities for Q1 2021 was CNY 220,317,632.56, an increase of 59.3% compared to CNY 138,364,960.42 in Q1 2020[47]. - Cash flow from investing activities showed a net outflow of CNY 324,030,839.64 in Q1 2021, compared to a net inflow of CNY 28,489,179.17 in Q1 2020[48]. - The total cash and cash equivalents at the end of Q1 2021 were CNY 705,076,989.66, down from CNY 652,910,810.34 in Q1 2020[49]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,228,301,233.43, an increase of 9.65% compared to the end of the previous year[11]. - Non-current assets totaled ¥1,757,303,851.40, compared to ¥1,593,173,288.20, reflecting an increase of about 10.3%[34]. - Current liabilities rose to ¥452,794,698.01 from ¥333,076,838.24, marking a significant increase of approximately 35.9%[34]. - Total liabilities amounted to ¥470,584,784.09, compared to ¥355,906,330.00, reflecting an increase of approximately 32.3%[36]. - The company’s total liabilities increased by ¥3,182,808.78 compared to the previous reporting period[55]. Shareholder Information - The total number of shareholders at the end of the reporting period was 67,300[15]. - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 32.28% of the shares[15]. - The major shareholder, Tibet Huaxi Pharmaceutical Group Co., Ltd., has pledged 30.842 million shares, accounting for 69.98% of its holdings and 12.44% of the company's total shares[29]. Investments and Projects - The company's construction in progress increased by CNY 1,377.84 million, a growth of 248.48%, primarily due to the initiation of a project by a subsidiary in Shanghai[22]. - The company completed the transfer of 89 out of 93 trademarks related to the acquired assets of AstraZeneca's Imdamo, with 27 out of 44 countries and regions having completed the MA conversion[26]. - The company has received approval for clinical trials of its mRNA COVID-19 vaccine in collaboration with Swei (Shanghai) Biotechnology Co., Ltd.[26]. - The company plans to continue to entrust AstraZeneca or Kangzhe (Hunan) Pharmaceutical Co., Ltd. for the production of Imdamo products after the marketing authorization holder change[26]. Financial Ratios and Returns - The weighted average return on equity increased by 0.80 percentage points to 5.91%[11]. - Basic earnings per share decreased by 13.70% to ¥0.63 due to a 40% increase in share capital compared to the previous reporting period[11]. Other Financial Metrics - The company’s tax and additional fees increased by CNY 17.20 million, a growth of 49.88%, due to the increase in sales revenue[24]. - The company reported a total cost of operations of ¥332,643,897.66 for Q1 2021, which is an increase from ¥198,141,264.78 in Q1 2020[41]. - Research and development expenses for Q1 2021 were ¥1,418,199.60, slightly up from ¥1,238,979.22 in Q1 2020[41].

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.37 billion, representing a 9.32% increase compared to ¥1.26 billion in 2019[20]. - The net profit attributable to shareholders for 2020 was approximately ¥418.1 million, a 33.87% increase from ¥312.3 million in 2019[20]. - The net cash flow from operating activities for 2020 was approximately ¥428.2 million, a decrease of 12.55% compared to ¥489.6 million in 2019[20]. - The total assets at the end of 2020 were approximately ¥2.94 billion, reflecting a 6.40% increase from ¥2.77 billion at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥2.58 billion, a 5.70% increase from ¥2.44 billion at the end of 2019[20]. - The basic earnings per share for 2020 were ¥1.69, a decrease of 3.43% compared to ¥1.75 in 2019[21]. - The weighted average return on net assets for 2020 was 15.09%, an increase of 1.60 percentage points from 13.49% in 2019[24]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately ¥365.3 million, a 19.87% increase from ¥304.8 million in 2019[20]. Revenue and Sales - In Q1 2020, the company's operating revenue was CNY 296,779,128.75, which increased to CNY 383,513,429.19 in Q4 2020, showing a growth of approximately 29.2% over the year[25]. - The company's main business revenue for the reporting period was 1,361.613 million yuan, with cardiovascular products Xinhuoshu, Yimuduo, and Nuodikan accounting for 94.55% of total revenue[33]. - Xinhuoshu sales contributed 70.42% of total revenue, increasing by 17.70% compared to the same period last year; Yimuduo accounted for 20.45%, with a growth of 2.53%; Nuodikan represented 3.68%, decreasing by 3.95%[33]. - The company achieved a revenue of CNY 1,373,105,105.65, representing a year-on-year increase of 9.32%[47]. - Sales of the main product, New活素, reached 2.6298 million units with a revenue of CNY 95,883.21 million, a year-on-year growth of 17.70%[41]. Product Development and R&D - The company is focused on expanding its business scope and product reserves to seek new profit growth points amid industry challenges[33]. - The company has initiated IIa phase clinical trials for the rhIL-1Ra eye drop project, with data analysis currently underway[41]. - The company has established a high-altitude medicinal herb planting base in Tibet for the artificial cultivation of红景天, achieving breakthroughs in cultivation technology[41]. - The company is actively pursuing external investments to increase product reserves, including exclusive sales rights for four in-development products from Amite and rights for COVID-19 vaccines from S Microbiology and Russian HV Company[38]. - The company is conducting a Phase IIa clinical trial for the recombinant human interleukin-1 receptor antagonist eye drops, with data analysis expected in 2021[77]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with Amite, S Microbiology, and Russian HV Company to enhance its product portfolio in medical devices and COVID-19 vaccines[33]. - The company is collaborating with HV Company for the Sputnik-V vaccine, committing to a minimum supply of 40 million doses for 2021, with associated risks in technology transfer and production[110]. - The company has initiated a collaboration with St. Microbiology for the development of mRNA vaccines, with a milestone payment of RMB 70 million already made[94]. Market Challenges and Opportunities - The ongoing COVID-19 pandemic has led to a significant decline in outpatient visits, adversely affecting sales of outpatient medications like Nuodikan and others[33]. - The aging population and increasing cardiovascular diseases present a growing market opportunity for the company's cardiovascular products[36]. - The pharmaceutical manufacturing industry is facing both opportunities and challenges due to policy changes and market dynamics, necessitating a focus on high clinical value products[67]. Environmental and Social Responsibility - The company actively engages in poverty alleviation efforts, directly supporting local farmers and improving their income through agricultural initiatives[143]. - The company donated protective supplies worth approximately CNY 5.23 million to support COVID-19 control efforts in severely affected areas[143]. - The company has committed to long-term support for industries in poverty-stricken areas, focusing on sustainable development and employment for local farmers[142]. Governance and Management - The company has established a transparent investor relations framework, ensuring shareholder rights and information access[143]. - The company has maintained independent operations from its controlling shareholder, ensuring no interference in decision-making processes[200]. - The company has implemented a comprehensive training program for its directors and senior management to enhance their professional capabilities[200]. - The company emphasizes the importance of creating value and has established a performance evaluation system aligned with its strategic development goals[195]. Shareholder Information - The total number of ordinary shares increased from 177,098,459 to 247,937,843 shares due to a cash dividend of 1.06 CNY per share and a bonus share issuance of 0.4 shares per share[159]. - The top five customers accounted for 20.10% of total sales, while the top five suppliers represented 67.70% of total purchases[57]. - The company has established a clear cash dividend policy in its articles of association, ensuring transparency in profit distribution[112].